Where can I trade BKYI after the Nasdaq suspension?

BKYI trades on OTC Markets starting May 13, 2026, under the same ticker symbol, though with lower liquidity and wider bid-ask spreads than on Nasdaq.

Can BIO-key get relisted on Nasdaq?

BIO-key has requested a Nasdaq Hearings Panel review, but under the new Rule 360, there is no guarantee of approval, and trading on Nasdaq is suspended during the appeals process.

What happens to a stock's price when it moves from Nasdaq to OTC?

Stocks typically see gap-down opens, reduced trading volume, and wider bid-ask spreads during Nasdaq-to-OTC transitions, as institutional investors with exchange-only mandates are forced to sell.

Does the BKYI delisting affect cybersecurity ETFs or broader indices?

No material impact is expected — BKYI's weighting in cybersecurity ETFs like BUG is negligible, and the event has no direct linkage to the Nasdaq 100 or S&P 500.

Quick Links

BIO-key (BKYI) Nasdaq Suspension: Microcap Compliance Trap Sends Stock to OTC Markets

Published: 2026-05-12 21:30:08 UTC

Tags:Global Regulatory Enforcement Wave

Key Takeaways

•BKYI suspended from Nasdaq effective May 12, 2026 close; OTC trading begins May 13 under the same ticker with significantly lower liquidity and wider spreads.
•Dual compliance failures: only 8 of the required 10 consecutive days above $1 bid price post-reverse split, plus an unresolved 10-K filing delay.
•Nasdaq's new Rule 360 imposes immediate suspension with no trading during appeals — eliminating the buffer that previously protected companies seeking hearings.
•Contagion to major indices or cybersecurity ETFs is negligible; this is a stock-specific microcap governance event.
•The 10-K filing outcome and Hearings Panel decision are binary catalysts — traders should await both before considering any re-entry.

According to a BIO-key GlobeNewswire press release dated May 12, 2026, BIO-key International (BKYI) — a fingerprint and identity authentication technology company — has been suspended from Nasdaq effe

Event Analysis

According to a BIO-key GlobeNewswire press release dated May 12, 2026, BIO-key International (BKYI) — a fingerprint and identity authentication technology company — has been suspended from Nasdaq effective the close of business May 12, 2026. Trading moves to OTC Markets under the same BKYI ticker starting May 13, 2026, following dual compliance failures that illustrate a textbook microcap governance breakdown.

The company fell victim to two simultaneous triggers: a failure to maintain a $1+ closing bid price for 10 consecutive days (achieving only 8 days post-reverse split) and an unfiled FY 2025 Form 10-K annual report. Critically, shareholders had approved a 1-for-10 reverse stock split on April 20, with trading commencing April 30 — yet the company missed Nasdaq's compliance window by just two days under new notification rules. Management has indicated the 10-K will be filed "next week," but Nasdaq's updated Rule 360 mandates immediate suspension with no trading permitted during the appeals process, eliminating the safety net that previously existed.

This event fits squarely within the broader global regulatory enforcement wave tightening standards for microcap Nasdaq listings. What distinguishes this case from routine delistings is the timing misalignment — the reverse split strategy was technically sound but procedurally flawed, wiping out the compliance benefit. BIO-key has requested a Nasdaq Hearings Panel review, though there is no assurance of relisting approval.

What This Means for Traders

The immediate trading implications for BKYI are sharply negative. Transition from Nasdaq to OTC Pink typically compresses volume by 20–50% and widens bid-ask spreads significantly, while institutional investors with exchange-only mandates are forced to exit positions. A gap-down open on OTC markets is the base case for May 13. The stock's liquidity profile deteriorates materially, making position sizing and exit timing critical considerations for any remaining holders.

For broader market participants, contagion risk is low-to-moderate. BIO-key's weighting in cybersecurity ETFs such as BUG (Global X Cybersecurity) is negligible. However, this event reinforces governance risk concerns across the 2026 Stocks Market Outlook — particularly for microcap Identity & Access Management names facing the same $1 bid price compliance pressure. Traders monitoring similar small-cap listings should treat this as a cautionary signal on reverse-split compliance timing under Nasdaq's tightened ruleset.

The key medium-term catalyst is binary: either the 10-K filing arrives clean and the Hearings Panel grants relisting consideration, or BKYI becomes permanently OTC-listed, triggering further institutional outflows and dilution risk. Until the filing materializes, the risk/reward profile is unfavorable. Position sizing should remain minimal given OTC liquidity constraints and wide spreads.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.

Frequently Asked Questions

BIO-key failed two simultaneous compliance requirements: its stock did not maintain a $1+ closing bid price for 10 consecutive days after a reverse split, and it has not filed its FY 2025 Form 10-K annual report.